GlassScriptPhysician profile
Ahmed Malik
NPI 1750476834
$1,751.41
in general payments reported to CMS, 2019-2025
23 companies · $27.49 in 2025
The $27.49 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.22 · 2020: $43.33 · 2021: $95.35 · 2022: $430 · 2023: $814 · 2024: $301 · 2025: $27.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.40 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $506.05 | 2020-2024 | |
| Actelion Pharmaceuticals US, INC. | $275.88 | 2023-2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $202.27 | 2019-2024 | Camzyos, Eliquis |
| Abbott Laboratories | $150.84 | 2022-2024 | Cardiomems, Jot Dx |
| Merck Sharp & Dohme LLC | $125.20 | 2022-2024 | Verquvo, Gardasil, Gardasil 9 |
| Edwards Lifesciences Corporation | $63.98 | 2019-2022 | |
| Amgen INC. | $59.47 | 2022-2023 | Repatha |
| Medtronic, INC. | $41.60 | 2021-2023 | Endurant Iis |
| Lexicon Pharmaceuticals, INC. | $38.09 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $36.80 | 2021-2022 | |
| Boston Scientific Corporation | $32.51 | 2022-2023 | |
| Daiichi Sankyo INC. | $27.49 | 2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $24.73 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.96 | 2023 | Lifevest |
| Heartflow, INC. | $18.51 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $18.04 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $17.09 | 2024 | Farxiga |
| Silk Road Medical, INC. | $16.77 | 2022 | |
| Chiesi USA, INC. | $16.71 | 2020 | |
| Pfizer INC. | $16.13 | 2022 | |
| Medtronic Vascular, INC. | $14.50 | 2019 | |
| Astellas Pharma US INC | $13.88 | 2022 | |
| Baylis Medical Company INC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.